A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer

被引：0
|
作者：
Boukovinas, I. [1 ]
Androulakis, N. [1 ]
Polyzos, A. [1 ]
Vardakis, N. [1 ]
Amarantidis, K. [1 ]
Bozionelou, V. [1 ]
Kouroussis, C. [1 ]
Giassas, S. [1 ]
Christophyllakis, C. [1 ]
Mavroudis, D. [1 ]
机构：
[1] Hellen Oncol Res Grp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4536
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Oxaliplatin, irinotecan, and 5-fluorouracil/leucovorin in advanced gastric adenocarcinoma: A phase II trial
    Comella, P.
    Lorusso, V.
    Maiorino, L.
    Casaretti, R.
    Cannone, M.
    Massidda, B.
    Farris, A.
    Leo, S.
    Roselli, M.
    Sandomenico, C.
    Mancarella, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [12] A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
    Cristina Gravalos
    Antonieta Salut
    Carlos García-Girón
    Rocío García-Carbonero
    Ana Isabel León
    Isabel Sevilla
    Joan Maurel
    Beatriz Esteban
    Eduardo García-Rico
    Adolfo Murias
    Hernán Cortés-Funes
    Clinical and Translational Oncology, 2012, 14 : 606 - 612
  • [13] A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
    Gravalos, Cristina
    Salut, Antonieta
    Garcia-Giron, Carlos
    Garcia-Carbonero, Rocio
    Isabel Leon, Ana
    Sevilla, Isabel
    Maurel, Joan
    Esteban, Beatriz
    Garcia-Rico, Eduardo
    Murias, Adolfo
    Cortes-Funes, Hernan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (08): : 606 - 612
  • [14] Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial)
    Martoni, Andrea Angelo
    Pinto, Carmine
    Di Fabio, Francesca
    Lelli, Giorgio
    Rojas Llimpe, Fabiola Lorena
    Gentile, Anna Lisa
    Mutri, Vita
    Ballardini, PierLuigi
    Giaquinta, Stefania
    Piana, Edera
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (18) : 3161 - 3168
  • [15] A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract
    Karachaliou, Niki
    Polyzos, Aris
    Kentepozidis, Nikolaos
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Milaki, Georgia
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    ONCOLOGY, 2010, 78 (5-6) : 356 - 360
  • [16] Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
    B Neri
    P Pantaleo
    E Giommoni
    R Grifoni
    C Paoletti
    V Rotella
    D Pantalone
    A Taddei
    A Mercatelli
    P Tonelli
    British Journal of Cancer, 2007, 96 : 1043 - 1046
  • [17] Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial.
    Schalhorn, A
    Ludwig, FW
    Quietzsch, D
    Maubach, PA
    Schlimok, G
    Lambertz, H
    Weigang-Koehler, K
    Schulze, M
    Schlag, R
    Grundeis, M
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 250S - 250S
  • [18] Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
    Neri, B.
    Pantaleo, P.
    Giommoni, E.
    Grifoni, R.
    Paoletti, C.
    Rotella, V.
    Pantalone, D.
    Taddei, A.
    Mercatelli, A.
    Tonelli, P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (07) : 1043 - 1046
  • [19] Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA study.
    Martoni, A
    Pinto, C
    Di Fabio, F
    Lelli, G
    Gentile, AL
    Llimpe, FLR
    Mutri, V
    Ballardini, PL
    Giaquinta, S
    Piana, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [20] Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer
    J Feliu
    C Castañón
    A Salud
    J R Mel
    P Escudero
    A Pelegrín
    L López-Gómez
    M Ruiz
    E González
    F Juárez
    J Lizón
    J Castro
    M González-Barón
    British Journal of Cancer, 2005, 93 : 1230 - 1235
12345